Market Expansion Immunovia is preparing to launch its highly accurate pancreatic cancer blood test, PancreaSure, in the United States in the second half of 2025, presenting a significant sales opportunity for partners and distributors in the US healthcare and diagnostics market.

Strategic Facility Moves The company's recent relocation of its U.S. headquarters and clinical laboratory to North Carolina’s Research Triangle Park indicates a focus on expanding American operations, which could facilitate local partnerships and increase market penetration.

Product Launch Success Since launching its first diagnostic, IMMray PanCan-d, in 2021, Immunovia has demonstrated consistent development and validation of its diagnostics, creating ongoing sales prospects for complementary testing solutions and follow-up diagnostics.

Funding and Revenue Potential With revenues between 1 and 10 million dollars and recent funding of 4.5 million dollars, Immunovia exhibits growth potential that can support marketing, sales expansion, and further technology development in targeted markets.

Regulatory and Clinical Focus The company's focus on launching tests as laboratory-developed tests and targeting pancreatic surveillance programs suggests opportunities for collaborative studies, clinical partnerships, and regulatory consulting to accelerate market access.